Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Purpose:

The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.


Study summary:

Objectives for this study are two-fold: 1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate, duration of response, and survival. 2. To assess the toxicity of SCH66366 in these patients.


Criteria:

- Diagnosis of Philadelphia chromosome (Ph) -positive CML in chronic or accelerated phase; - Failure to respond to or intolerance to imatinib mesylate (Gleevec); - Age >/= 16 years; - Life expectancy of >/= 2 months; - Performance status 2 or better (Zubrod); - Adequate renal and hepatic functions (creatinine and bilirubin </= 2 mg/dl); - Adequate cardiac function; - Not candidates for or have refused allogeneic transplantation; - Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole), macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs (phenobarbital, phenytoin, carbamazepine), rifampin or isoniazid.


NCT ID:

NCT00038597


Primary Contact:

Principal Investigator
Jorge Cortes, MD
UT MD Anderson Cancer Center


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.